SRRK
Scholar Rock Holding Corporation$46.55+0.26 (+0.55%)Prev Close$46.29·MCap$5.44B·P/E—·Vol799.8K·Yield—
▲
Buys (12M)
1
$18.81M
▼
Sells (12M)
42
$24.31M
◆
Net Activity
Net Seller
$5.51M
●
Active Insiders
16
last 12 mo
Over the past 12 months, insider activity at Scholar Rock Holding Corporation (SRRK) has been mixed between buying and selling, with 1 insider purchase totaling $18.81M and 42 insider sales totaling $24.31M. The most recent insider transaction was by Hallal David (director, officer: Chief Executive Officer), who sold $1.52M worth of shares on Apr 20, 2026. Scholar Rock Holding Corporation operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $5.44B.
SRRK Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 20, 2026 | Hallal David | director, officer: Chief Executive Officer | Sell | 30,615 | $49.57 | $1.52M | 1,639,034 |
| Apr 20, 2026 | Sinha Vikas | officer: Chief Financial Officer | Sell | 10,410 | $49.57 | $516.1K | 619,856 |
| Apr 20, 2026 | Vaishnaw Akshay | director, officer: President of R&D | Sell | 12,246 | $49.57 | $607.1K | 630,542 |
| Apr 20, 2026 | Woods Keith | officer: Chief Operating Officer | Sell | 10,220 | $49.57 | $506.7K | 620,055 |
| Feb 25, 2026 | Qatanani Mo | officer: CHIEF SCIENTIFIC OFFICER | Sell | 8,484 | $47.07 | $399.4K | 99,502 |
| Feb 19, 2026 | Ho Junlin | officer: GENERAL COUNSEL | Sell | 9,580 | $46.53 | $445.7K | 241,545 |
| Feb 19, 2026 | Marantz Jing L. | officer: CHIEF MEDICAL OFFICER | Sell | 4,157 | $46.53 | $193.4K | 126,012 |
| Feb 19, 2026 | Parlavecchio Caryn | officer: CHRO | Sell | 9,035 | $46.53 | $420.4K | 169,087 |
| Feb 19, 2026 | Qatanani Mo | officer: CHIEF SCIENTIFIC OFFICER | Sell | 7,989 | $46.53 | $371.7K | 106,929 |
| Feb 17, 2026 | Ho Junlin | GENERAL COUNSEL | Sell | 9,580 | $46.53 | $445.7K | 0 |
| Feb 17, 2026 | Marantz Jing L. | CHIEF MEDICAL OFFICER | Sell | 4,157 | $46.53 | $193.4K | 0 |
| Feb 17, 2026 | Parlavecchio Caryn | CHRO | Sell | 9,035 | $46.53 | $420.4K | 0 |
| Feb 17, 2026 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 7,989 | $46.53 | $371.7K | 0 |
| Jan 23, 2026 | Qatanani Mo | officer: CHIEF SCIENTIFIC OFFICER | Sell | 14,898 | $46.71 | $695.9K | 98,439 |
| Jan 21, 2026 | Ho Junlin | officer: GENERAL COUNSEL | Sell | 8,016 | $44.48 | $356.5K | 214,553 |
| Jan 21, 2026 | Marantz Jing L. | officer: CHIEF MEDICAL OFFICER | Sell | 5,798 | $44.48 | $257.9K | 95,687 |
| Jan 21, 2026 | Parlavecchio Caryn | officer: CHRO | Sell | 6,600 | $44.48 | $293.6K | 148,864 |
| Jan 21, 2026 | Qatanani Mo | officer: CHIEF SCIENTIFIC OFFICER | Sell | 8,406 | $44.48 | $373.9K | 100,558 |
| Jan 16, 2026 | Qatanani Mo | officer: CHIEF SCIENTIFIC OFFICER | Sell | 13,112 | $45.20 | $592.6K | 108,964 |
| Jan 15, 2026 | Hallal David | director, officer: Chief Executive Officer | Sell | 57,450 | $42.70 | $2.45M | 1,541,645 |
| Jan 15, 2026 | Sinha Vikas | officer: Chief Financial Officer | Sell | 16,755 | $42.70 | $715.4K | 583,245 |
| Jan 15, 2026 | Vaishnaw Akshay | director, officer: President of R&D | Sell | 20,438 | $42.70 | $872.7K | 595,767 |
| Jan 15, 2026 | Woods Keith | officer: Chief Operating Officer | Sell | 16,746 | $42.70 | $715.1K | 583,254 |
| Dec 5, 2025 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 136,462 | $45.21 | $6.17M | 108,964-56% |
| Oct 7, 2025 | AKKARAJU SRINIVAS | Buy | 500,439 | $37.58 | $18.81M | 500,439 | |
| Sep 24, 2025 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 3,353 | $30.67 | $102.8K | 108,964 |
| Sep 17, 2025 | Peng Katie | Sell | 1,006 | $32.53 | $32.7K | 33,990 | |
| Sep 17, 2025 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 3,178 | $33.52 | $106.5K | 112,317 |
| Aug 19, 2025 | Parlavecchio Caryn | CHRO | Sell | 2,178 | $31.17 | $67.9K | 155,464 |
| Jul 18, 2025 | FLIER JEFFREY S. | Sell | 11,136 | $40.02 | $445.7K | 0Exit | |
| Jul 10, 2025 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 24,066 | $34.44 | $828.9K | 115,495 |
| Jun 25, 2025 | FLIER JEFFREY S. | Sell | 31,452 | $32.58 | $1.02M | 26,836-54% | |
| Jun 17, 2025 | Ho Junlin | GENERAL COUNSEL | Sell | 7,442 | $32.00 | $238.2K | 222,569 |
| Jun 17, 2025 | Parlavecchio Caryn | CHRO | Sell | 6,186 | $32.00 | $198.0K | 157,642 |
| Jun 17, 2025 | Peng Katie | Sell | 3,031 | $31.97 | $96.9K | 34,974 | |
| Jun 17, 2025 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 3,668 | $32.00 | $117.4K | 139,561 |
| May 30, 2025 | Brudnick Richard | Sell | 6,075 | $29.72 | $180.5K | 16,457-27% | |
| May 30, 2025 | Burow Kristina | Sell | 5,400 | $29.72 | $160.5K | 25,471 | |
| May 30, 2025 | FLIER JEFFREY S. | Sell | 6,075 | $29.73 | $180.6K | 29,045 | |
| May 30, 2025 | Gilman Michael | Sell | 3,375 | $29.72 | $100.3K | 57,961 | |
| May 30, 2025 | Reed Joshua | Sell | 5,400 | $29.72 | $160.5K | 16,232 | |
| May 30, 2025 | Vaishnaw Akshay | President of R&D | Sell | 6,750 | $29.72 | $200.6K | 617,825 |
| Apr 29, 2025 | Sacco Tracey | Chief Commercial Officer | Sell | 5,000 | $32.83 | $164.1K | 71,834 |
| Mar 25, 2025 | Moore Erin | Interim PFO and PAO | Sell | 13,564 | $33.12 | $449.2K | 82,609 |
| Mar 25, 2025 | Sacco Tracey | Chief Commercial Officer | Sell | 6,500 | $33.08 | $215.0K | 76,750 |
| Mar 19, 2025 | Peng Katie | Sell | 1,006 | $34.42 | $34.6K | 30,319 | |
| Mar 12, 2025 | Myles Edward H | COO & CFO | Sell | 142,292 | $35.62 | $5.07M | 140,740-50% |
| Feb 20, 2025 | Backstrom Jay T. | CHIEF EXECUTIVE OFFICER | Sell | 18,372 | $36.83 | $676.6K | 311,991 |
| Feb 20, 2025 | Ho Junlin | GENERAL COUNSEL | Sell | 5,742 | $36.83 | $211.5K | 189,295 |
| Feb 20, 2025 | Myles Edward H | COO & CFO | Sell | 7,809 | $36.83 | $287.6K | 140,740 |
Showing 1–50 of 102
1 / 3
SRRK Insider Buying Activity
The following table shows recent insider purchases of Scholar Rock Holding Corporation (SRRK) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 7, 2025 | AKKARAJU SRINIVAS | Buy | 500,439 | $37.58 | $18.81M | 500,439 |
SRRK Insider Selling Activity
The following table shows recent insider sales of Scholar Rock Holding Corporation (SRRK) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 20, 2026 | Hallal David | director, officer: Chief Executive Officer | Sell | 30,615 | $49.57 | $1.52M | 1,639,034 |
| Apr 20, 2026 | Sinha Vikas | officer: Chief Financial Officer | Sell | 10,410 | $49.57 | $516.1K | 619,856 |
| Apr 20, 2026 | Vaishnaw Akshay | director, officer: President of R&D | Sell | 12,246 | $49.57 | $607.1K | 630,542 |
| Apr 20, 2026 | Woods Keith | officer: Chief Operating Officer | Sell | 10,220 | $49.57 | $506.7K | 620,055 |
| Feb 25, 2026 | Qatanani Mo | officer: CHIEF SCIENTIFIC OFFICER | Sell | 8,484 | $47.07 | $399.4K | 99,502 |
| Feb 19, 2026 | Ho Junlin | officer: GENERAL COUNSEL | Sell | 9,580 | $46.53 | $445.7K | 241,545 |
| Feb 19, 2026 | Marantz Jing L. | officer: CHIEF MEDICAL OFFICER | Sell | 4,157 | $46.53 | $193.4K | 126,012 |
| Feb 19, 2026 | Parlavecchio Caryn | officer: CHRO | Sell | 9,035 | $46.53 | $420.4K | 169,087 |
| Feb 19, 2026 | Qatanani Mo | officer: CHIEF SCIENTIFIC OFFICER | Sell | 7,989 | $46.53 | $371.7K | 106,929 |
| Feb 17, 2026 | Ho Junlin | GENERAL COUNSEL | Sell | 9,580 | $46.53 | $445.7K | 0 |
| Feb 17, 2026 | Marantz Jing L. | CHIEF MEDICAL OFFICER | Sell | 4,157 | $46.53 | $193.4K | 0 |
| Feb 17, 2026 | Parlavecchio Caryn | CHRO | Sell | 9,035 | $46.53 | $420.4K | 0 |
| Feb 17, 2026 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 7,989 | $46.53 | $371.7K | 0 |
| Jan 23, 2026 | Qatanani Mo | officer: CHIEF SCIENTIFIC OFFICER | Sell | 14,898 | $46.71 | $695.9K | 98,439 |
| Jan 21, 2026 | Ho Junlin | officer: GENERAL COUNSEL | Sell | 8,016 | $44.48 | $356.5K | 214,553 |
| Jan 21, 2026 | Marantz Jing L. | officer: CHIEF MEDICAL OFFICER | Sell | 5,798 | $44.48 | $257.9K | 95,687 |
| Jan 21, 2026 | Parlavecchio Caryn | officer: CHRO | Sell | 6,600 | $44.48 | $293.6K | 148,864 |
| Jan 21, 2026 | Qatanani Mo | officer: CHIEF SCIENTIFIC OFFICER | Sell | 8,406 | $44.48 | $373.9K | 100,558 |
| Jan 16, 2026 | Qatanani Mo | officer: CHIEF SCIENTIFIC OFFICER | Sell | 13,112 | $45.20 | $592.6K | 108,964 |
| Jan 15, 2026 | Hallal David | director, officer: Chief Executive Officer | Sell | 57,450 | $42.70 | $2.45M | 1,541,645 |
| Jan 15, 2026 | Sinha Vikas | officer: Chief Financial Officer | Sell | 16,755 | $42.70 | $715.4K | 583,245 |
| Jan 15, 2026 | Vaishnaw Akshay | director, officer: President of R&D | Sell | 20,438 | $42.70 | $872.7K | 595,767 |
| Jan 15, 2026 | Woods Keith | officer: Chief Operating Officer | Sell | 16,746 | $42.70 | $715.1K | 583,254 |
| Dec 5, 2025 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 136,462 | $45.21 | $6.17M | 108,964-56% |
| Sep 24, 2025 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 3,353 | $30.67 | $102.8K | 108,964 |
| Sep 17, 2025 | Peng Katie | Sell | 1,006 | $32.53 | $32.7K | 33,990 | |
| Sep 17, 2025 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 3,178 | $33.52 | $106.5K | 112,317 |
| Aug 19, 2025 | Parlavecchio Caryn | CHRO | Sell | 2,178 | $31.17 | $67.9K | 155,464 |
| Jul 18, 2025 | FLIER JEFFREY S. | Sell | 11,136 | $40.02 | $445.7K | 0Exit | |
| Jul 10, 2025 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 24,066 | $34.44 | $828.9K | 115,495 |
| Jun 25, 2025 | FLIER JEFFREY S. | Sell | 31,452 | $32.58 | $1.02M | 26,836-54% | |
| Jun 17, 2025 | Ho Junlin | GENERAL COUNSEL | Sell | 7,442 | $32.00 | $238.2K | 222,569 |
| Jun 17, 2025 | Parlavecchio Caryn | CHRO | Sell | 6,186 | $32.00 | $198.0K | 157,642 |
| Jun 17, 2025 | Peng Katie | Sell | 3,031 | $31.97 | $96.9K | 34,974 | |
| Jun 17, 2025 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 3,668 | $32.00 | $117.4K | 139,561 |
| May 30, 2025 | Brudnick Richard | Sell | 6,075 | $29.72 | $180.5K | 16,457-27% | |
| May 30, 2025 | Burow Kristina | Sell | 5,400 | $29.72 | $160.5K | 25,471 | |
| May 30, 2025 | FLIER JEFFREY S. | Sell | 6,075 | $29.73 | $180.6K | 29,045 | |
| May 30, 2025 | Gilman Michael | Sell | 3,375 | $29.72 | $100.3K | 57,961 | |
| May 30, 2025 | Reed Joshua | Sell | 5,400 | $29.72 | $160.5K | 16,232 | |
| May 30, 2025 | Vaishnaw Akshay | President of R&D | Sell | 6,750 | $29.72 | $200.6K | 617,825 |
| Apr 29, 2025 | Sacco Tracey | Chief Commercial Officer | Sell | 5,000 | $32.83 | $164.1K | 71,834 |
| Mar 25, 2025 | Moore Erin | Interim PFO and PAO | Sell | 13,564 | $33.12 | $449.2K | 82,609 |
| Mar 25, 2025 | Sacco Tracey | Chief Commercial Officer | Sell | 6,500 | $33.08 | $215.0K | 76,750 |
| Mar 19, 2025 | Peng Katie | Sell | 1,006 | $34.42 | $34.6K | 30,319 | |
| Mar 12, 2025 | Myles Edward H | COO & CFO | Sell | 142,292 | $35.62 | $5.07M | 140,740-50% |
| Feb 20, 2025 | Backstrom Jay T. | CHIEF EXECUTIVE OFFICER | Sell | 18,372 | $36.83 | $676.6K | 311,991 |
| Feb 20, 2025 | Ho Junlin | GENERAL COUNSEL | Sell | 5,742 | $36.83 | $211.5K | 189,295 |
| Feb 20, 2025 | Myles Edward H | COO & CFO | Sell | 7,809 | $36.83 | $287.6K | 140,740 |
SRRK Insiders
Similar Stocks to SRRK
VRTX
Vertex Pharmaceuticals Incorporated
$429.47+0.81%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$734.06-1.39%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$303.44-1.64%
$41.24B
INSM
Insmed Incorporated
$135.11-0.64%
$30.79B
RVMD
Revolution Medicines, Inc.
$144.62+9.92%
$29.51B
UTHR
United Therapeutics Corporation
$566.69+0.03%
$25.13B
MRNA
Moderna, Inc.
$47.16-3.17%
$21.42B
RPRX
Royalty Pharma plc
$49.40-0.50%
$21.20B